BioCryst is profitable. Now it wants to buy more rare disease drugs

Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.

Published Aug 28, 2026Aug 28, 2026 · 8:00 PMOriginal source: Consumer News and Business Channel19 reads

Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.

ORIGINAL SOURCE

Consumer News and Business Channel

This report is indexed by BAGANBAZAR GRAPH with its original publisher named and linked for readers.